US stocks fell for a second day Tuesday as a back-up in interest rates overshadowed a solid start to earnings reporting season.
Gene therapy company Genprex surged another 125% in morning trading on Tuesday after soaring 266% on Monday. Genprex’s gene therapy trial progress are driving strong interest.
Last week, US-based Genprex has received approval from the Safety Review Committee (SRC) to proceed to the highest dose group of 0.12mg/kg in the Phase I portion of the Acclaim-3 trial of Reqorsa Gene Therapy (quaratusugene ozeplasmid) for extensive stage small cell lung cancer (ES-SCLC).
The trial is designed to evaluate the gene therapy, along with Genentech’s Tecentriq (atezolizumab) as maintenance therapy, for ES-SCLC patients.
This latest move comes after the company completed the 0.09mg/kg dose group.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。